117440 ⎘
Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5) Dynamin GTPase (3.6.5.5)
Biomarkers for Long COVID
#2THERAPY BY TRANS-SPLICING OF OPA1 PRE-MESSENGER RNAS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OPA1 GENE MUTATIONS
#3NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE
#4FUNCTIONAL NUCLEIC ACID MOLECULES
#5METHODS AND COMPOSITIONS FOR TREATING OCULAR DISEASES AND DISORDERS
#6ALLELE-SPECIFIC SILENCING THERAPY FOR DYNAMIN 2-RELATED DISEASES
#7TREATMENT OF OPTIC ATROPHY
#8DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES
#9DESIGNING CUSTOMIZED PROTEIN-SPECIFIC-BUFFER SYSTEM
#10MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING CENTRONUCLEAR MYOPATHY
#11Gene sequence of recombinant human type II mitochondrial dynein-like GTPase and uses thereof
#12Allele-specific silencing therapy for dynamin 2-related diseases
#13DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
#14Dynamin 2 inhibitor for the treatment of centronuclear myopathies
#15Allele-specific silencing therapy for Dynamin 2-related diseases
#16Designing customized protein-specific buffer system
#17Dynamin 2 inhibitor for the treatment of Duchenne's muscular dystrophy
#18Dynamin 2 inhibitor for the treatment of centronuclear myopathies
#19Dynamin mediated diseases and associated methods and products
#20AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS
#21Dynamin mediated diseases and associated methods and products